TABLE 2.
Hypothyroidism | Adrenal Insufficiency | Growth Hormone Deficiency | |||||||
---|---|---|---|---|---|---|---|---|---|
Present (n=35) * |
Absent (n=78) * |
P-value | Present (n=20) * |
Absent (n=94) * |
P-value | Present (n=71) * |
Absent (n=36) * |
P-value | |
Mean age at diagnosis, yr (SD) | 8.22 (4.29) | 7.40 (3.54) | 0.29 | 7.76 (3.82) | 7.36 (3.58) | 0.66 | 7.00 (3.17) | 7.95 (4.18) | 0.19 |
Sex, n(%) | 0.82 | 0.17 | 0.96 | ||||||
Male | 24 (68.6) | 56 (71.8) | 17 (85.0) | 65 (69.2) | 51 (71.8) | 26 (72.2) | |||
Female | 11 (31.4) | 22 (28.2) | 3 (15.0) | 29 (30.9) | 20 (28.2) | 10 (27.8) | |||
Race/Ethnicity, n(%) | 0.18 | 0.28 | 0.08 | ||||||
Non-Hispanic White | 18 (51.4) | 27 (34.6) | 5 (25.0) | 42 (44.7) | 33 (46.5) | 13 (36.1) | |||
Hispanic | 13 (37.1) | 28 (35.9) | 10 (50.0) | 31 (33.0) | 26 (36.6) | 11 (30.6) | |||
Non-Hispanic Black | 3 (8.6) | 14 (18.0) | 4 (20.0) | 12 (12.8) | 8 (11.3) | 5 (13.9) | |||
Non-Hispanic Other | 1 (2.9) | 9 (11.5) | 1 (5.0) | 9 (9.6) | 4 (5.6) | 7 (19.4) | |||
CSI radiation dose, n(%) | 0.19 | 0.29 | 0.82 | ||||||
<30 Gy | 21 (60.0) | 58 (74.4) | 12 (60.0) | 68 (72.3) | 48 (67.6) | 25 (71.4) | |||
≥30 Gy | 14 (40.0) | 20 (25.6) | 8 (40.0) | 26 (27.7) | 23 (32.4) | 10 (28.6) | |||
Treatment Protocol, n(%) | 0.35 | 0.30 | 0.04 | ||||||
SJMB 96 | 7 (20.0) | 14 (18.0) | 2 (10.0) | 20 (21.3) | 11 (15.5) | 4 (11.4) | |||
SJMB 03 | 17 (48.6) | 35 (44.9) | 9 (45.0) | 43 (45.7) | 37 (52.1) | 14 (40.0) | |||
COG AA9961 | 8 (22.9) | 13 (16.7) | 7 (35.0) | 14 (14.9) | 14 (19.7) | 5 (14.3) | |||
SJMB 12 | 0 (0.0) | 8 (10.3) | 1 (5.0) | 7 (7.5) | 6 (8.5) | 3 (8.6) | |||
Other | 3 (8.6) | 8 (10.3) | 1 (5.0) | 10 (10.6) | 3 (4.2) | 9 (25.7) |
Number of cases and controls may not combine to a total of 118 patients since patients were excluded if there was insufficient laboratory data to determine their endocrinopathy status.
SD, standard deviation; CSI, craniospinal irradiation; SJMB, St. Jude Medulloblastoma; COG, Children’s Oncology Group